Conclusion: Recombinant feline HGF treatment suppressed the progression of NASH in a CDAA diet feeding mouse model.This suggests that recombinant HGF protein has therapeutic potential for NASH. This evidence concerns the gene HGF and metabolic dysfunction-associated steatohepatitis.